Post-poliomyelitis syndrome as a possible viral disease
| Autor: | John R. McFarlane, Mary-ann Liethof, Andreina Baj, Antonio Toniolo, M. Colombo, Joan L. Headley |
|---|---|
| Jazyk: | angličtina |
| Předmět: |
Microbiology (medical)
Weakness Pediatrics medicine.medical_specialty Epidemiology etiology prevalence Pathogenesis Persistent infection medicine.disease_cause lcsh:Infectious and parasitic diseases ICD G14 Atrophy Post-polio syndrome Poliomyelitis eradication medicine Humans lcsh:RC109-216 Post-polio Syndrome ICD G14 poliovirus mutations chronic infection prevalence treatment etiology pathogenesis health care economics and organizations treatment business.industry Poliovirus General Medicine mutations medicine.disease infection Poliomyelitis chronic Infectious Diseases Etiology Physical therapy Viral disease Postpoliomyelitis Syndrome Therapy medicine.symptom business |
| Zdroj: | International Journal of Infectious Diseases, Vol 35, Iss C, Pp 107-116 (2015) |
| ISSN: | 1201-9712 |
| DOI: | 10.1016/j.ijid.2015.04.018 |
| Popis: | Summary This review summarizes current concepts on post-polio syndrome (PPS), a condition that may arise in polio survivors after partial or complete functional recovery followed by a prolonged interval of stable neurological function. PPS affects 15–20 million people worldwide. Epidemiological data are reported, together with the pathogenic pathways that possibly lead to the progressive degeneration and loss of neuromuscular motor units. As a consequence of PPS, polio survivors experience new weakness, generalized fatigue, atrophy of previously unaffected muscles, and a physical decline that may culminate in the loss of independent life. Emphasis is given to the possible pathogenic role of persistent poliovirus infection and chronic inflammation. These factors could contribute to the neurological and physical decline in polio survivors. A perspective is then given on novel anti-poliovirus compounds and monoclonal antibodies that have been developed to contribute to the final phases of polio eradication. These agents could also be useful for the treatment or prevention of PPS. Some of these compounds/antibodies are in early clinical development. Finally, current clinical trials for PPS are reported. In this area, the intravenous infusion of normal human immunoglobulins appears both feasible and promising. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|